GPR17 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1127003	0.54	10/20
SCHEMBL1590066	0.57	7/20
SCHEMBL1359693	0.50	7/20
SCHEMBL1603375	0.33	7/20
SCHEMBL975002	0.50	5/20
SCHEMBL314687	0.34	5/20
Hydrochloric Acid (SCHEMBL1042399)	0.33	5/20
Hydrochloric Acid (SCHEMBL1044115)	0.33	5/20
Hydrochloric Acid (SCHEMBL1044825)	0.33	5/20
SCHEMBL1602100	0.33	5/20
SCHEMBL1602378	0.33	5/20
SCHEMBL1602877	0.33	5/20
SCHEMBL1602993	0.33	5/20
Arsenic (SCHEMBL1603010)	0.33	5/20
SCHEMBL1603028	0.33	5/20
SCHEMBL1603306	0.33	5/20
SCHEMBL1603355	0.33	5/20
SCHEMBL1603399	0.33	5/20
SCHEMBL1603405	0.33	5/20
SCHEMBL1603442	0.33	5/20

Clinical trials — most relevant to GPR17 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Open-label Study of the Effects of Montelukast in Patients With Chronic Cough	PHASE4	COMPLETED
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma	PHASE4	COMPLETED
Wheeze and Intermittent Treatment	PHASE3	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Montelukast for Early Life Wheezing	PHASE2/PHASE3	COMPLETED
Predicting the Response to Montelukast by Genetic Variation in Asthmatics	PHASE3	COMPLETED
Triamcinolone Versus Methylprednisolone in Transversus Abdominis Plane Block	PHASE2/PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Treatment of Bronchial Asthma With Borage and Echium Seed Oils	PHASE1/PHASE2	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Study of the Mechanisms of Asthma	PHASE1	COMPLETED
Role of TLR4 in Environmental Asthma	PHASE1	COMPLETED
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers	EARLY_PHASE1	UNKNOWN
GSNOR Phenotyping/GSNO Challenge in Severe Asthma	EARLY_PHASE1	COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)	EARLY_PHASE1	RECRUITING
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial	nan	COMPLETED
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia	nan	COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.	nan	COMPLETED
The Severe Asthma Research Program III-Boston Clinical Site	nan	COMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
Gastroparesis Registry 3	nan	COMPLETED
The Genetics of Environmental Asthma	nan	COMPLETED
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis	nan	WITHDRAWN
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome	nan	ACTIVE_NOT_RECRUITING
Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GPR17 binder may also engage these)

Protein	Name	Similarity
Q6NS65	—	0.998	Q6NS65 →
Q09QM4	—	0.997	Q09QM4 →
Q149R9	—	0.986	Q149R9 →
CYSLTR2	Cysteinyl leukotriene receptor 2	0.982	landscape →
F8VQN3	—	0.981	F8VQN3 →
Q8C131	—	0.981	Q8C131 →
B0UXR0	—	0.980	B0UXR0 →
P48042	—	0.980	P48042 →
D4A7K7	—	0.980	D4A7K7 →
P59902	—	0.980	P59902 →
Q3ZC80	—	0.979	Q3ZC80 →
HCAR1	Hydroxycarboxylic acid receptor 1	0.979	landscape →
O09027	—	0.978	O09027 →
Q95N03	—	0.978	Q95N03 →
GPR174	Probable G-protein coupled receptor 174	0.977	landscape →
Q920E0	—	0.977	Q920E0 →
P49650	—	0.977	P49650 →
Q3U6B2	—	0.977	Q3U6B2 →
P2RY1	P2Y purinoceptor 1	0.977	landscape →
P30558	—	0.977	P30558 →
P34997	—	0.976	P34997 →
O00590	—	0.976	O00590 →
Q3U507	—	0.976	Q3U507 →
LPAR5	Lysophosphatidic acid receptor 5	0.976	landscape →
P49652	—	0.976	P49652 →
P49651	—	0.976	P49651 →
Q2Y2P0	—	0.975	Q2Y2P0 →
Q3UJF0	—	0.975	Q3UJF0 →
P35411	—	0.975	P35411 →
A5PLE7	—	0.975	A5PLE7 →